Free Submission Public Relations & NewsPR-inside.com
 
DeutschEnglish

Get the latest news
with our RSS feed
rss feed
Add to My Yahoo!
More information
Business

Research and Markets: This In-Depth Company Profile of Cubist Pharmaceuticals Inc Includes an Analysis of Company Strategy, a SWOT Analysis and 5-Year Financial Insights


Print article Print article
Refer this article Refer to a friend
© Business Wire 2008
2008-10-09 11:54:04 -

www.researchandmarkets.com - Research and Markets (www.researchandmarkets.com/research/751563/cubist_pharmaceuti) has announced the addition of the "Cubist Pharmaceuticals Inc: Strategic Corporate Assessment - Strategy, SWOT Analysis and 5-year Financial Insights with In-depth Company Profile" company profile to their offering.

Cubist Pharmaceuticals is a biopharmaceutical company focused on the research, development and commercialization of pharmaceutical products that address unmet medical needs in the acute

care environment. Cubicin, Cubists major product, is approved for multiple indications in many countries. In the US, Cubicin is being marketed for the treatment of complicated skin structure infections (cSSI).

Scope

-- Contains corporate strategy, value chain presence and SWOT Analysis

-- Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors

-- Includes information on suppliers/partners, shareholding structure and key employees with biographies

Highlights of this title

Cubist has one marketed product, Cubicin, an antibiotic from a class of antiinfectives called lipopeptides, for the treatment of complicated skin and skin structure infections, and for other blood-stream infections. The company's research and development programs include lipopeptide programs.

Cubist has research collaboration with Ilypsa to develop ILY103, a non-antibiotic, toxin binder therapy for the treatment of clostridium difficile associated diarrhea which is in preclinical trials.

Cubist derives its revenues from the product sales of Cubicin and other revenues which includes license agreements revenues, Small Business Innovation Research (SBIR) and grant revenue. Cubists total revenues increased at a CAGR of 103% during 2002-2006, from $11 million in 2002 to $195 million in 2006.

Key reasons to purchase this title

-- Access all the important information and analysis on the company in a single report

-- Understand company's strengths, weaknesses, opportunities and threats along with business strategy and value chain

-- Gain access to company's adjusted five year financial data along with key ratios and market capitalization -0- Key Topics Covered: - Summary - Company Structure - Company Overview and Key Facts - Business Description - History - Company Financials - Products & Services - Competitors and Strategic Business Relationships - SWOT Analysis - Value Chain Analysis - Scorecard Analysis - Key Employees - Financial and Operational Overview - Table of Figures - Table of Tables

For more information visit www.researchandmarkets.com/research/751563/cubist_pharmaceuti

Source: Datamonitor

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
Fax (USA): 646-607-1907
Fax (International): +353-1-481-1716


Disclaimer: (c) 2009 Business Wire. All of the news releases contained herein are protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Business Wire's members, who warrant that they are solely responsible for the content, accuracy and originality of the information contained therein. All reproduction, other than for an individual user's personal reference, is prohibited without prior written permission.
Terms & Conditions | Privacy | About us | Contact PR-inside.com